Tamoxifen metabolism and pharmacogenetics in breast cancer

Dezentjé, V.O. (2013)

Doctoral Thesis

Not all hormone receptor positive breast cancer patients benefit from tamoxifen treatment, but may be nonetheless exposed to its side effects (e.g. hot flashes). Tamoxifen needs bioactivation by formation of the metabolite endoxifen, which is mainly catalyzed by the enzyme CYP2D6. In this thesis, we studied the variation in tamoxifen metabolism in relation to endoxifen serum concentration, tamoxifen efficacy and side effects, focusing on CYP2D6 activity and pharmacogenetics. The importance of good methodology for genotyping and endoxifen measurement was exemplified. In a large trial population, no association between CYP2D6 genotype and disease free survival or the occurence of hot flashes was found, although polymorphisms in the estrogen receptor-1 and UGT2B15 might be related to clinical outcome. Adherence, but not the concomitant use of CYP2D6 inhibiting medication was associated with breast cancer recurrence. CYP2D6 genotype and endoxifen-guided tamoxifen dose escalation led to an increase in endoxifen serum levels and a new 13C-Dextromethorphan breath test was used for phenotyping CYP2D6, which correlated well with CYP2D6 genotype and endoxifen levels. Finally, the CYP2D6 phenotype and endoxifen serum levels are currently prospectively related to breast cancer recurrence. This may lead to therapeutic drug monitoring and selection of patients who benefit most from tamoxifen.

• CYP2D6
• Pharmacogenetics
• Breast cancer
• Tamoxifen

• All authors: Dezentjé, V.O.
• Supervisor: Guchelaar, H.J.; Nortier, J.W.R.; Gelderblom, A.J.
• Co-supervisor: Straaten, R.J.H.M. van
• Qualification: Doctor (dr.)
• Awarding Institution: Leiden University Medical Center (LUMC), Leiden University
• Date: 2013-10-02
• ISBN (print): 9789490791209
• Sponsorship: AZL Onderzoeks- en Ontwikkelingskrediet (OOK) Apotheek; Afdeling Klinische Oncologie LUMC